I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Risk of major adverse limb events in patients with type 2 d..:
Yen-Chieh Lee
;
Yaa-Hui Dong
;
Wei-Shun Yang
...
https://www.frontiersin.org/articles/10.3389/fphar.2022.869804/full. , 2022
Link:
https://doi.org/10.3389/fphar.2022.869804
RT Journal T1 <Title>Risk of major adverse limb events in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based retrospective cohort study</Title> UL https://suche.suub.uni-bremen.de/peid=base-ftdoajarticles:oai:doaj.org_article:ba9e2ec19cc54c338b2aee2fa3ff3865&Exemplar=1&LAN=DE A1 Yen-Chieh Lee A1 Yaa-Hui Dong A1 Wei-Shun Yang A1 Li-Chiu Wu A1 Jou-Wei Lin A1 Chia-Hsuin Chang PB Frontiers Media S.A. YR 2022 K1 sodium-glucose cotransporter-2 inhibitor K1 critical limb ischemia K1 lower extremity amputation K1 glucagon-like peptide-1 receptor agonist K1 dipeptidyl peptidase-4 inhibitor K1 type 2 diabetes K1 Therapeutics. Pharmacology K1 RM1-950 JF https://www.frontiersin.org/articles/10.3389/fphar.2022.869804/full LK http://dx.doi.org/https://doi.org/10.3389/fphar.2022.869804 DO https://doi.org/10.3389/fphar.2022.869804 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)
